Lennie Ryer
Director/Board Member presso Aegera Therapeutics, Inc.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Clive Beddoe | M | 77 | 9 anni | |
| Perry B. Molinoff | M | 84 |
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Freda Miller | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | 24 anni |
| Alex MacKenzie | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | 24 anni |
| Gerald Connor | M | 78 | 9 anni | |
| Robert Korneluk | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | 24 anni |
| Jonathan Ronkai | M | - |
Canadian Tax Foundation
| - |
| Faralee Allyn Chanin | F | - |
Canadian Tax Foundation
| - |
| Jerry Rubin | M | - |
Canadian Tax Foundation
| - |
| David Harris | M | - |
Canadian Tax Foundation
| - |
| Jamie Golombek | M | - |
Canadian Tax Foundation
| - |
| Patricia A. McIver | F | - |
Canadian Tax Foundation
| - |
| Paul Rokeby | M | 64 |
Canadian Tax Foundation
| - |
| Rachel Colabella | F | - |
Canadian Tax Foundation
| - |
| Brian J. Reddy | M | - |
Canadian Tax Foundation
| - |
| Tim Rorabeck | M | - |
Canadian Tax Foundation
| - |
| Shane Brown | M | - |
Canadian Tax Foundation
| - |
| Dave Brown | M | 64 |
Canadian Tax Foundation
| - |
| Craig Prenter | M | - |
Canadian Tax Foundation
| - |
| Rodney B. Johnston | M | - |
Canadian Tax Foundation
| - |
| James Millar | M | - |
Canadian Tax Foundation
| - |
| Mao Sun | M | 47 |
Canadian Tax Foundation
| - |
| Chris Tsiofas | M | 56 |
Canadian Tax Foundation
| - |
| Mark Bernard | M | - |
Canadian Tax Foundation
| - |
| R. Daren Baxter | M | 60 |
Canadian Tax Foundation
| - |
| Suzanne Desrosiers | F | - |
Canadian Tax Foundation
| - |
| Shawn D. Porter | M | - |
Canadian Tax Foundation
| - |
| Christine van Cauwenberghe | F | - |
Canadian Tax Foundation
| - |
| Guy Masson | M | - |
Canadian Tax Foundation
| - |
| Vincent Rizzi | M | - |
Canadian Tax Foundation
| - |
| David Walsh | M | - |
Canadian Tax Foundation
| - |
| Michael B. Cross | M | 59 |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Lawrence P. Kelly | M | 74 |
Canadian Tax Foundation
| - |
| Louis P. Lacasse | M | 67 |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Trudie Resch | F | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | 17 anni |
| Samuel Minzberg | M | 67 |
Canadian Tax Foundation
| - |
| George A. Caines | M | 86 |
Canadian Tax Foundation
| - |
| Dennis Leroy Nerland | M | 69 |
Canadian Tax Foundation
| - |
| Ronald Appleby | M | - |
Canadian Tax Foundation
| - |
| Joe Regan | M | 56 |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Andrew Burgess | M | 70 |
Canadian Tax Foundation
| - |
| John W. Gillard | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Robert Penner | M | 80 |
Canadian Tax Foundation
| - |
| Serge Langford | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| Douglas R. Brett | M | - |
Canadian Tax Foundation
| - |
| Rocco Cappuccitti | M | - |
Canadian Tax Foundation
| - |
| Inès Holzbaur | M | - |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | - |
| George D. Goulet | M | - |
Canadian Tax Foundation
| - |
| Kelly Lutz | M | - |
Canadian Tax Foundation
| - |
| Neil D. Chander | M | 51 |
Canadian Tax Foundation
| - |
| Allan Beach | M | - |
Canadian Tax Foundation
| - |
| Robin A. W. Elliott | M | - |
Canadian Tax Foundation
| - |
| Anthony L. Soda | M | - |
Canadian Tax Foundation
| - |
| Brent Perry | M | - |
Canadian Tax Foundation
| - |
| Terry C. Ofremchuk | M | 73 |
Canadian Tax Foundation
| - |
| André Lacroix | M | - |
Canadian Tax Foundation
| - |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Peter Winkley | M | - | 8 anni | |
| Chester Ku | M | - | - | |
| Wilmot Matthews | M | 87 | 8 anni | |
| Christian Petzelt | M | 81 | 1 anni | |
| David Alan Williams | M | 82 | 8 anni | |
| Samira Sakhia | F | 55 | 14 anni | |
| Paul J. Mountain | M | - | 8 anni | |
| David MacNaughtan | M | 57 | 3 anni | |
| Allan Pronovost | M | - | 1 anni | |
| Cameron Richard Prange | M | 69 | 2 anni | |
| Mike Polonsky | M | - |
ConjuChem Biotechnologies, Inc. /Old/
 ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | - |
| Jean M. Silveri | F | - |
ConjuChem Biotechnologies, Inc. /Old/
ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | - |
| Luc Mainville | M | 60 | 1 anni | |
| Bianca Knop | F | - | - | |
| Geoffrey Galley | M | 84 | 1 anni | |
| Randal Chase | M | 74 |
ConjuChem Biotechnologies, Inc. /Old/
ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | 5 anni |
| Ger J. van Amersfoort | M | - | - | |
| Steve Perrone | M | - |
ConjuChem Biotechnologies, Inc. /Old/
ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | 8 anni |
| Michael Freeman | M | - | - | |
| Craig Saxton | M | 81 |
ConjuChem Biotechnologies, Inc. /Old/
ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | 4 anni |
| Jacques R. Lapointe | M | - |
ConjuChem Biotechnologies, Inc. /Old/
ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | 8 anni |
| Mark D. Perrin | M | 67 |
ConjuChem Biotechnologies, Inc. /Old/
ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | 4 anni |
| Thomas R. Ulich | M | 70 |
ConjuChem Biotechnologies, Inc. /Old/
ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | 4 anni |
| Felix Baker | M | 55 |
ConjuChem Biotechnologies, Inc. /Old/
ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | 8 anni |
| Mike Edmonds | M | - |
Les Équipements Power Survey Ltée
 Les Équipements Power Survey Ltée Alternative Power GenerationUtilities Power Survey & Equipment Ltd. provides solutions for measuring and analyzing the intensity of harmonic currents and voltages. Its products include capacitor banks, harmonic filters, accessories and distribution. The firm offers power factor correction, harmonic distortion correction, start-up and commissioning, preventive maintenance, and technical training services for commercial and institutional, industrial and manufacturing, mining, metal and mineral, oil and gas, grid and transportation industries. The company was founded by 1948 and is headquartered in Montreal, Canada. | - |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Canada | 76 | 93.83% |
| Stati Uniti | 5 | 6.17% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Lennie Ryer
- Contatti personali
